You are here: Home » 2021 » July » Archives for 2nd

Parexel to be Acquired by EQT Private Equity and Goldman Sachs Asset Management

BOSTON and DURHAM, N.C., July 02, 2021 (GLOBE NEWSWIRE) — Parexel, a leading global clinical research organization (CRO) focused on development and delivery of innovative new therapies to advance patient health, today announced the execution of a definitive merger agreement under which it will be acquired by EQT IX fund ("EQT Private Equity") and the Private Equity business within Goldman Sachs Asset Management ("Goldman Sachs") from Pamplona Capital Management LP for $8.5 billion.

"Over the past 18 months Parexel has continued its strong growth trajectory delivering on its patients–first focus and accelerating new therapies to patients in need around the world," said Parexel CEO Jamie Macdonald. "With the market for outsourced clinical research services anticipated to grow at a conservative CAGR of 8 to 9 percent, our focus remains on advancing and innovating Parexel to meet our customers' needs across the evolving clinical development landscape. EQT and Goldman Sachs support this vision and are committed to investing in Parexel and our people to capitalize on this exciting market opportunity and make a difference for patients."

Eric Liu, Partner and Global Co–Head of Healthcare at EQT, commented, "We have followed Parexel closely during the past few years and have been impressed by the company's development and trajectory. Our investment in Parexel reflects EQT's thematic focus on the life sciences industry, as well as our commitment to partner with businesses that have a positive impact on society. We are excited to partner with Goldman Sachs for the next stage of Parexel's journey, and to back Jamie, who prior to his role at Parexel had been a long–time senior advisor to EQT, as well as the rest of the Parexel team."

Jo Natauri, Partner and Global Head of Private Healthcare Investing within Goldman Sachs Asset Management, commented, "We are thrilled to partner with Jamie Macdonald, the entire Parexel management team and EQT to support Parexel, which has a distinguished track record of delivering clinical excellence to their large pharma and biotech customers globally. We believe this investment will accelerate Parexel's growth as it builds on the company's global footprint, strong operational capabilities and expansive healthcare network."

John Halsted, Managing Partner, Pamplona Capital Management, commented, "We're very proud of Parexel's progress over the past four years and the important work they do in helping bring exciting new therapies to patients in need. In particular, they successfully adapted the business to work in the midst of a global pandemic, and supported the development of therapies to combat the COVID–19 pandemic itself. We wish them every success in their next phase of growth.”

"We have enjoyed our partnership with Pamplona, and thank them for their leadership and support in helping to transform Parexel under their ownership," concluded Mr. Macdonald. "Over the past months, our ability to pivot and adapt have fostered new ways of working while developing a strong track record of quality and delivery for customers around the world. As we continue in this new era of clinical development and focus aggressively on meeting our customers' needs for innovation in such areas as Real World Evidence, Decentralized Clinical Trials, Biostatistics and Data Management "" and in key regions such as Asia/Pacific where we're among the largest and longest–tenured CROs "" we're excited to be partnering with EQT and Goldman Sachs. We look forward to benefitting from their strong industry experience and to further accelerating Parexel as one of the world's leading and fastest–growing CROs."

The transaction is subject to customary conditions, including receipt of applicable regulatory approvals. Evercore acted as the financial advisor to Parexel, and Kirkland & Ellis LLP provided legal counsel in connection with the transaction. Goldman Sachs and Jefferies LLC acted as financial advisors to EQT Private Equity and Goldman Sachs Asset Management, and Simpson Thacher & Bartlett LLP provided legal counsel in connection with the transaction.

About Parexel
Parexel supports the development of innovative new medicines to improve the health of patients. We provide services to help life sciences and biopharmaceutical clients everywhere transform scientific discoveries into new treatments. From decentralized clinical trials to regulatory consulting services to leveraging real world insights, our therapeutic, technical, and functional ability is underpinned by a deep conviction in what we do. Parexel was named "Best Contract Research Organization" in December 2020 by an independent panel for Informa Pharma Intelligence. For more information, visit parexel.com and follow us on LinkedIn, Twitter, and Instagram.

About EQT
EQT is a purpose–driven global investment organization with more than EUR 67 billion in assets under management across 26 active funds. EQT funds have portfolio companies in Europe, Asia–Pacific and the Americas with total sales of approximately EUR 29 billion and more than 175,000 employees. EQT works with portfolio companies to achieve sustainable growth, operational excellence and market leadership. For more information, visit www.eqtgroup.com or follow EQT on LinkedIn, Twitter, YouTube and Instagram.

About Goldman Sachs Asset Management Private Equity
Bringing together traditional and alternative investments, Goldman Sachs Asset Management provides clients around the world with a dedicated partnership and focus on long–term performance. As the primary investing area within Goldman Sachs (NYSE: GS), we deliver investment and advisory services for the world's leading institutions, financial advisors and individuals, drawing from our deeply connected global network and tailored expert insights, across every region and market""overseeing more than $2 trillion in assets under supervision worldwide as of March 31, 2021. Driven by a passion for our clients' performance, we seek to build long–term relationships based on conviction, sustainable outcomes, and shared success over time. Goldman Sachs Asset Management invests in the full spectrum of alternatives, including private equity, growth equity, private credit, real estate and infrastructure. Established in 1986, the Private Equity business within Goldman Sachs Asset Management has invested over $75 billion since inception. We combine our global network of relationships, our unique insight across markets, industries and regions, and the worldwide resources of Goldman Sachs to build businesses and accelerate value creation across our portfolios. Follow us on LinkedIn.

About Pamplona Capital Management
Pamplona Capital Management is a specialist investment manager established in 2005 that provides an alternative investment platform across private equity and other diversified strategies. With offices in New York, London, Madrid, and Malta, Pamplona manages over $11 billion in assets for a variety of clients including public pension funds, international wealth managers, multinational corporations, family offices, and funds of hedge funds. Pamplona invests long–term capital across the capital structure of its portfolio companies in both public and private market situations.

CONTACTS

For Parexel:
Lori Dorer
Senior Vice President, Corporate Communications
+1 513 496 8121

Lindsay LeCain
Real Chemistry
+ 1 508 259 9521

For EQT:
Daniel Yunger, Kekst CNC, + 1 917 574 8582
EQT Press Office, press@eqtpartners.com, +46 8 506 55 334

For Goldman Sachs:
Leslie Shribman
+1 212 902 5400

For Pamplona Capital Management:
Ed Orlebar, TB Cardew
ed.orlebar@tbcardew.com
+44 (0)7738724630


GLOBENEWSWIRE (Distribution ID 8274570)

Nyxoah Announces Pricing of Nasdaq Public Offering

Mont–Saint–Guibert, Belgium "" July 2, 2021, 2:40pm CET / 8:40am ET "" Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the pricing of its initial public offering in the United States (the “Offering”) of 2,835,000 ordinary shares at a price to the public of US$ 30 per share for total gross proceeds of US$ 85.1 million before deducting underwriting discounts and commissions and estimated offering expenses.

In addition, Nyxoah has granted the underwriters a 30–day option to purchase up to an additional 425,250 ordinary shares at the initial public offering price less underwriting discounts and commissions, to cover over–allotments, if any.

The closing of the Offering is expected to occur on July 7, 2021, subject to the satisfaction of customary closing conditions.

Nyxoah's ordinary shares are listed on Euronext Brussels under the symbol "NYXH". The ordinary shares are expected to begin trading on the NASDAQ Global Market on July 2, 2021 under the same symbol.

Piper Sandler, Stifel and Cantor are acting as joint book–running managers for the offering. Degroof Petercam is acting as a co–manager.

A registration statement relating to the ordinary shares was filed with the Securities and Exchange Commission ("SEC") and declared effective on June 30, 2021. This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification or publication of an offering prospectus under the securities laws of any such state or jurisdiction.

The offering of ordinary shares was made only by means of a prospectus. When available, a copy of the final prospectus can be obtained from Piper Sandler & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by e–mail at prospectus@psc.com, or by phone at (800) 747–3924; Stifel, Nicolaus & Company, Incorporated at Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364–2720, or by email at syndprospectus@stifel.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022; email: prospectus@cantor.com.

Forward–Looking Statements
This press release includes certain disclosures that contain "forward–looking statements," including, without limitation, statements regarding the closing of the offering. Forward–looking statements are based on Nyxoah's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ. Forward–looking statements contained in this announcement are made as of this date, and Nyxoah undertakes no duty to update such information except as required under applicable law.

IMPORTANT INFORMATION
No public offering will be made and no one has taken any action that would, or is intended to, permit a public offering in any country or jurisdiction, other than the United States, where any such action is required, including in Belgium. Belgian investors, other than qualified investors within the meaning of the Belgian Act of 11 July 2018 on the public offering of securities and the admission of securities to be traded on a regulated market, will not be eligible to participate in the offering (whether in Belgium or elsewhere). The transaction to which this press release relates will only be available to, and will be engaged in only with, in member states of the European Economic Area, persons falling within the meaning of Article 2(e) of Regulation (EU) 2017/1129 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market (the “Prospectus Regulation”), and in the United Kingdom, investment professionals falling within article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the “Order”), persons falling within article 49 (2), (a) to (d) of the Order and other persons to whom it may lawfully be communicated. A listing prospectus will be prepared by Nyxoah in accordance with Article 3 of the Prospectus Regulation for the purpose of having the new ordinary shares, issued pursuant to the Offering or (as the case may be) the exercise by the underwriters of their 30–day option to purchase additional ordinary shares, admitted to trading on Euronext Brussels.

Contacts:
Nyxoah
Fabian Suarez, Chief Financial Officer
fabian.suarez@nyxoah.com
+32 10 22 24 55

Gilmartin Group
Vivian Cervantes
IR@nyxoah.com

Attachment


GLOBENEWSWIRE (Distribution ID 1000514150)